RT Journal Article
SR Electronic
T1 Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.19.21266555
DO 10.1101/2021.11.19.21266555
A1 Demonbreun, Alexis R.
A1 Sancilio, Amelia
A1 Vaught, Lauren A.
A1 Reiser, Nina L.
A1 Pesce, Lorenzo
A1 McNally, Elizabeth M.
A1 McDade, Thomas W.
YR 2021
UL http://medrxiv.org/content/early/2021/11/21/2021.11.19.21266555.abstract
AB Two-dose messenger RNA vaccines (BNT162b2/Pfizer and mRNA-1273/Moderna) against SARS-CoV-2 were rolled out in the US in December 2020, and provide protection against hospitalization and death from COVID-19 for at least six months. Breakthrough infections have increased with waning immunity and the spread of the B.1.617.2 (Delta) variant in summer 2021, prompting approval of boosters for all adults over 18. We measured anti-receptor binding domain (RBD) IgG and surrogate virus neutralization of the interaction between SARS-CoV-2 spike protein and the human angiotensin-converting enzyme (ACE2) receptor, before and after boosters in N=33 healthy adults. We document large antibody responses 6-10 days after booster, with antibody levels that exceed levels documented after natural infection with COVID-19, after two doses of vaccine, or after both natural infection and vaccination. Surrogate neutralization of B.1.617.2 is high but reduced in comparison with wild-type SARS-CoV-2. These data support the use of boosters to prevent breakthrough infections and suggest that antibody-mediated immunity may last longer than after the second vaccine dose.Competing Interest StatementThomas McDade has a financial interest in EnMed Microanalytics, a company that specializes in laboratory testing of dried blood spot samples. All other authors declare no conflicts of interest.Funding StatementSupported by the National Science Foundation 2035114, NIH 3UL1TR001422-06S4, Northwestern University Office of Research, and a generous gift from Dr. Andrew Senyei and Noni Senyei. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All research activities were implemented under protocols approved by the institutional review board at Northwestern University (#STU00212457 and #STU00212472).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for the potentially identifiable dataset should be made by qualified researchers trained in human subject confidentiality protocols to Dr. Thomas McDade at Northwestern University.